Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3778 versus placebo and loratadine in seasonal allergic rhinitis
2005-002805-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing AZD3778 sequence, Placebo sequence and Loratadine sequence (3 arms). Primary endpoints: Total Nasal Symptom Score (TNSS) morning, Total Nasal Symptom Score (TNSS) evening and 1 more. Started Aug 2005; status: completed.
02
Drugs
AZD3778loratadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2005-002805-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002805-21.